IP Verse

Optimized Factor Viii Gene - EP2956477

The patent EP2956477 was granted to Biogen MA on Jan 24, 2024. The application was originally filed on Feb 14, 2014 under application number EP14751254A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2956477

BIOGEN MA
Application Number
EP14751254A
Filing Date
Feb 14, 2014
Status
Patent Maintained As Amended
Dec 22, 2023
Grant Date
Jan 24, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

J A KEMPAug 17, 2021J A KEMPADMISSIBLE

Patent Citations (135) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0295597
DESCRIPTIONUS2003069395
DESCRIPTIONUS2003235536
DESCRIPTIONUS2007021494
DESCRIPTIONUS2007231329
DESCRIPTIONUS2007237765
DESCRIPTIONUS2007237766
DESCRIPTIONUS2007237767
DESCRIPTIONUS2007243188
DESCRIPTIONUS2007248603
DESCRIPTIONUS2007286859
DESCRIPTIONUS2008004206
DESCRIPTIONUS2008033413
DESCRIPTIONUS2008057056
DESCRIPTIONUS2008153751
DESCRIPTIONUS2008161243
DESCRIPTIONUS2008194481
DESCRIPTIONUS2008260738
DESCRIPTIONUS2008261877
DESCRIPTIONUS2009042283
DESCRIPTIONUS2009058322
DESCRIPTIONUS2009087411
DESCRIPTIONUS2010239554
DESCRIPTIONUS2010292130
DESCRIPTIONUS2010323956
DESCRIPTIONUS2011046060
DESCRIPTIONUS2011046061
DESCRIPTIONUS2011077199
DESCRIPTIONUS2011172146
DESCRIPTIONUS4683195
DESCRIPTIONUS4683202
DESCRIPTIONUS4704362
DESCRIPTIONUS4800159
DESCRIPTIONUS4868112
DESCRIPTIONUS4965188
DESCRIPTIONUS5112950
DESCRIPTIONUS5171844
DESCRIPTIONUS5304489
DESCRIPTIONUS5543502
DESCRIPTIONUS5595886
DESCRIPTIONUS5610278
DESCRIPTIONUS5648260
DESCRIPTIONUS5658570
DESCRIPTIONUS5712122
DESCRIPTIONUS5736137
DESCRIPTIONUS5739277
DESCRIPTIONUS5741957
DESCRIPTIONUS5789203
DESCRIPTIONUS5834250
DESCRIPTIONUS5849992
DESCRIPTIONUS5869046
DESCRIPTIONUS5972885
DESCRIPTIONUS6030613
DESCRIPTIONUS6048720
DESCRIPTIONUS6060447
DESCRIPTIONUS6086875
DESCRIPTIONUS6096871
DESCRIPTIONUS6121022
DESCRIPTIONUS6159730
DESCRIPTIONUS6193980
DESCRIPTIONUS6194551
DESCRIPTIONUS6228620
DESCRIPTIONUS6242195
DESCRIPTIONUS6277375
DESCRIPTIONUS6316226
DESCRIPTIONUS6346513
DESCRIPTIONUS6413777
DESCRIPTIONUS6485726
DESCRIPTIONUS6528624
DESCRIPTIONUS6538124
DESCRIPTIONUS6696245
DESCRIPTIONUS6737056
DESCRIPTIONUS6821505
DESCRIPTIONUS6998253
DESCRIPTIONUS7041635
DESCRIPTIONUS7083784
DESCRIPTIONUS7317091
DESCRIPTIONUS7404956
DESCRIPTIONWO0009560
DESCRIPTIONWO0032767
DESCRIPTIONWO0042072
DESCRIPTIONWO02060919
DESCRIPTIONWO0244215
DESCRIPTIONWO03074569
DESCRIPTIONWO03077834
DESCRIPTIONWO2004016750
DESCRIPTIONWO2004029207
DESCRIPTIONWO2004035752
DESCRIPTIONWO2004044859
DESCRIPTIONWO2004063351
DESCRIPTIONWO2004074455
DESCRIPTIONWO2004099249
DESCRIPTIONWO2005040217
DESCRIPTIONWO2005070963
DESCRIPTIONWO2005077981
DESCRIPTIONWO2005092925
DESCRIPTIONWO2005123780
DESCRIPTIONWO2006019447
DESCRIPTIONWO2006047350
DESCRIPTIONWO2006085967
DESCRIPTIONWO2008012543
DESCRIPTIONWO2008143954
DESCRIPTIONWO2008155134
DESCRIPTIONWO2010091122
DESCRIPTIONWO2010140148
DESCRIPTIONWO2010144502
DESCRIPTIONWO2010144508
DESCRIPTIONWO2011005968
DESCRIPTIONWO2011028228
DESCRIPTIONWO2011028229
DESCRIPTIONWO2011028344
DESCRIPTIONWO2012006635
DESCRIPTIONWO8704187
DESCRIPTIONWO8807089
DESCRIPTIONWO9109122
DESCRIPTIONWO9614339
DESCRIPTIONWO9805787
DESCRIPTIONWO9823289
DESCRIPTIONWO9951642
DESCRIPTIONWO9958572
INTERNATIONAL-SEARCH-REPORTUS2004147436
INTERNATIONAL-SEARCH-REPORTUS2009017533
INTERNATIONAL-SEARCH-REPORTUS2010284971
INTERNATIONAL-SEARCH-REPORTUS2013024960
INTERNATIONAL-SEARCH-REPORTUS6924365
OPPOSITIONUS6316226
OPPOSITIONWO03100053
OPPOSITIONWO2009075772
OPPOSITIONWO2011004361
OPPOSITIONWO2011005968
OPPOSITIONWO2012170289
SEARCHUS2009042283
SEARCHWO2007149852
SEARCHWO2011005968
SEARCHWO2013009627

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation", Europapress, (20090311), pages 1 - 3, Europapress, URL: https://www.europapress.es/comunicados/empresas-00908/noticia-comunicado-european-commission-approves-refacto-aftm-as-variation-to-the-refactor-marketing-authorisation-20090311172203.html, (20220629), XP055936780-
OPPOSITION- Anonymous, "Search Orphan Drug Designations and Approvals", FDA, (19960802), pages 1 - 2, FDA, URL: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=094495, (20220629), XP055936786-
OPPOSITION- Comparison of codon usage frequency in SEQ ID NO: 1 and SEQ ID: 3 of the Patent and SEQ ID: 5 of D1-
OPPOSITION- Comparison of in vivo FVIII activity after expression with codon optimised FVIII (SEQ ID: 1) and non-optimised FVIII (SEQ ID: 3)-
OPPOSITION- LIND, P. ET AL., "Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.", European Journal of Biochemistry, Published by Springer-Verlag on behalf of the Federation of European Biochemical Societies, (19950801), vol. 232., no. 01., doi:10.1111/j.1432-1033.1995.tb20776.x, ISSN 0014-2956, pages 19 - 27.-
OPPOSITION- N. J. Ward et al, "Codon optimization of human factor VIII cDNAs leads to high-level expression", Blood, (20110120), vol. 117, no. 3, doi:10.1182/blood-2010-05-282707, ISSN 00064971, pages 798 - 807-
OPPOSITION- SANDBERG H, ET AL., "STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII", Seminars in Hematology, W.B. Saunders Co., US, US , (20010401), vol. 38, no. 02, SUPPL. 04, doi:10.1053/shem.2001.25888, ISSN 0037-1963, pages 04 - 12-
OPPOSITION- Sequence alignment of SEQ ID NO: 1 of the opposed patent and SEQ IDNOs: 4-6 of D1-
OPPOSITION- Sequence alignment of SEQ ID NOs: 1 and 3 of the opposed patent-
OPPOSITION- VEHAR et al., Nature, (19841122), vol. 312, no. 5992, pages 337 - 42-
OPPOSITION- W. Cao et al, "Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20080527), vol. 105, no. 21, doi:10.1073/pnas.0801735105, ISSN 0027-8424, pages 7416 - 7421-
OPPOSITION- William R. Strohl, "Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters", BIODRUGS, Adis International Ltd., NZ, NZ , (20150801), vol. 29, no. 4, doi:10.1007/s40259-015-0133-6, ISSN 1173-8804, pages 215 - 239-
OPPOSITION- William R. Strohl, "Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters", BIODRUGS, Adis International Ltd., NZ, NZ , (20150801), vol. 29, no. 4, doi:10.1007/s40259-015-0133-6, ISSN 1173-8804, pages 215 - 239, XP055304636
OPPOSITION- VEHAR et al., Nature, (19841122), vol. 312, no. 5992, pages 337 - 42, XP002017256
OPPOSITION- SANDBERG H, ET AL., "STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII", Seminars in Hematology, W.B. Saunders Co., US, US , (20010401), vol. 38, no. 02, SUPPL. 04, doi:10.1053/shem.2001.25888, ISSN 0037-1963, pages 04 - 12, XP001223580
OPPOSITION- W. Cao et al, "Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20080527), vol. 105, no. 21, doi:10.1073/pnas.0801735105, ISSN 0027-8424, pages 7416 - 7421, XP055569884
OPPOSITION- LIND, P. ET AL., "Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.", European Journal of Biochemistry, Published by Springer-Verlag on behalf of the Federation of European Biochemical Societies, (19950801), vol. 232., no. 01., doi:10.1111/j.1432-1033.1995.tb20776.x, ISSN 0014-2956, pages 19 - 27., XP002111900
OPPOSITION- N. J. Ward et al, "Codon optimization of human factor VIII cDNAs leads to high-level expression", Blood, (20110120), vol. 117, no. 3, doi:10.1182/blood-2010-05-282707, ISSN 00064971, pages 798 - 807, XP055052195
SEARCH- N. J. WARD ET AL, "Codon optimization of human factor VIII cDNAs leads to high-level expression", BLOOD, (20110120), vol. 117, no. 3, doi:10.1182/blood-2010-05-282707, ISSN 0006-4971, pages 798 - 807, XP055052195 [I] 1,3-15 * abstract * * page 799, column l, paragraph 2 - column r, paragraph 1 * * page 799, column r, paragraph 2 - page 800, column l, paragraph 1 * * page 800, column l, paragraph l - column r, paragraph 2 * * page 803, column l, paragraph 2 - page 804, column l, paragraph 1 * * page 804, column l, paragraph l - page 805, column r, paragraph 1 * * figures 3-4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents